We are live on ! Find out more
LIVN icon

LivaNova

79.83 USD
-0.20
0.25%
At close Updated Aug 28, 10:36 AM EDT
1 day
-0.25%
5 days
1.5%
1 month
-2.75%
3 months
9.3%
6 months
13.6%
Year to date
31.65%
1 year
43.97%
5 years
-3.13%
10 years
31.62%
 

About: UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Employees: 3,300

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 29.4%
Neutral 64.7%
Negative 5.9%
Neutral
Seeking Alpha
3 days ago
Artisan International Small-Mid Fund Q2 2026 Portfolio Review
Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.
Artisan International Small-Mid Fund Q2 2026 Portfolio Review
Positive
Zacks Investment Research
21 days ago
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
Neutral
Seeking Alpha
22 days ago
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
Neutral
MarketBeat
22 days ago
LivaNova Q2 Earnings Call Highlights
LivaNova NASDAQ: LIVN reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjusted free-cash-flow forecast to account for increased investment in manufacturing capacity, innovation and IT infrastructure.
LivaNova Q2 Earnings Call Highlights
Neutral
Zacks Investment Research
23 days ago
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
23 days ago
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?
Positive
Zacks Investment Research
23 days ago
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LivaNova (LIVN) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.05 per share a year ago.
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
Neutral
Business Wire
23 days ago
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared to the prior-year period Second-quarter U.S. GAAP diluted earnings per share of $1.93 and adjusted diluted earnings per sh.
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Negative
Zacks Investment Research
1 month ago
3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdles
GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.
3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdles
Positive
Zacks Investment Research
1 month ago
LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?
LivaNova (LIVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?
Price charts implemented using Lightweight Charts™